Longevity Medical Institute launches intranasal regenerative neurology platform

Longevity Medical Institute has rolled out a non-invasive intranasal delivery system for selected neurological therapies in San José del Cabo, Mexico. The program is meant to give physicians another option alongside intrathecal treatment for patients evaluated for regenerative neurological care.

Why it matters: - The new platform could broaden delivery options for regenerative neurological therapies without requiring a lumbar puncture in selected cases. - The system is designed to support nose-to-brain transport, which may help bypass part of the blood-brain barrier. - Longevity Medical Institute says the approach adds flexibility for physicians treating patients with neurological disorders.

What happened: - Longevity Medical Institute launched its Regenerative Neurological Therapy Program in San José del Cabo, Baja California Sur, Mexico, on July 23, 2026. - The program features an advanced intranasal delivery platform for regenerative therapies aimed toward the brain through the nasal cavity. - Dr. Kirk Sanford, founder and CEO of Longevity Medical Institute, said the platform expands the institute’s ability to personalize treatment. - The institute said patients can now access both intrathecal and non-invasive intranasal administration, depending on diagnosis, clinical findings and treatment goals.

The details: - The brain’s blood-brain barrier blocks many compounds from reaching the central nervous system. - Intrathecal administration remains a direct route into cerebrospinal fluid, but it requires a lumbar puncture. - The intranasal platform targets the upper nasal cavity near the olfactory region, rather than the lower nasal passages used by conventional sprays. - Research has shown that compounds delivered to the olfactory region may travel toward the brain along olfactory and trigeminal nerve pathways. - The system uses an electronically controlled nebulizer instead of a traditional spray pump. - The nebulizer produces microscopic aerosol droplets and delivers them gradually over several minutes. - The controlled delivery is intended to increase contact time in the olfactory region, reduce medication loss into the throat and improve consistency. - The platform is used exclusively for regenerative therapies, including mesenchymal stem cells, MSC-derived exosomes and selected therapeutic peptides. - Treatment recommendations come from the institute’s multidisciplinary physician team after a neurological evaluation that may include advanced imaging, laboratory testing, neurological examination and medical history review. - The broader neurological program also includes intravenous regenerative therapies, intrathecal administration in the institute’s fully licensed operating room when indicated, hyperbaric oxygen therapy, advanced neurological imaging and multidisciplinary physician care. - The institute’s website is More information.

Between the lines: - The launch reflects a push to make regenerative neurology less invasive while keeping intrathecal treatment available for cases where physicians consider it necessary. - The company is positioning the platform around published nose-to-brain delivery research, but the article also notes that larger randomized trials are still needed to define who benefits most and how durable the results may be. - Human studies of MSCs and MSC-derived exosomes have reported encouraging safety findings across conditions including ischemic stroke, multiple sclerosis, ALS, spinal cord injury, Parkinson’s disease, Alzheimer’s disease, traumatic brain injury and cerebral palsy. - Published studies have also examined possible effects on neurological function, disease stabilization, walking ability, cognition, quality of life and neuroinflammation.

What's next: - Longevity Medical Institute says treatment selection will continue to depend on physician evaluation, published evidence, patient-specific factors and clinical judgment. - The institute indicates regenerative neurological therapies remain a fast-growing area of translational medicine, even as larger trials are still needed. - Future research will likely focus on which patients respond best and how long benefits last.

The bottom line: - Longevity Medical Institute is betting that a non-invasive intranasal route can expand access to selected regenerative neurological treatments while preserving more invasive options for cases that need them.